High-Intensity PEMF Therapy and Chronic Pain: What It Is, Evidence and Clinical Application

Chronic musculoskeletal pain affects millions of people and is one of the leading causes of disability worldwide. Among the emerging technologies being explored as a complement to conventional treatments, pulsed electromagnetic field (PEMF) therapy has attracted growing interest in the scientific community. A device that applies this principle in a specific way is the high-intensity pulsed electromagnetic field system CTU Mega 20, manufactured by CTU Technology (Italy).

In this article we review what this therapy involves, the proposed mechanisms of action, what the available scientific evidence says, and how it is integrated into a neurorehabilitation programme such as the one we offer at GNeuro, in Ourense.

Important note: This article is for informational and educational purposes only. Any therapeutic decision must always be made under medical supervision.

What Is the CTU Mega 20 High-Intensity PEMF System?

The CTU Mega 20 is a therapeutic system based on the generation of high-intensity pulsed electromagnetic fields (PEMF), designed and manufactured by CTU Technology, an Italian company specialising in electromedical devices. Unlike conventional PEMF equipment, the CTU Mega 20 uses considerably higher electromagnetic field intensities, allowing it to reach deeper tissues.

To understand how it works, two key concepts are important:

Pulsed electromagnetic fields (PEMF): These are electromagnetic fields applied intermittently (pulsed) to biological tissues. PEMF therapy has been used for decades in various clinical indications, particularly in fracture consolidation and, more recently, in the management of musculoskeletal pain. Its theoretical basis rests on the ability of electromagnetic fields to interact with biological tissues at the cellular level.

Diamagnetism: Diamagnetism is a universal physical property of matter. All materials exhibit some degree of diamagnetism — a tendency to be repelled by an external magnetic field. In biological tissues, most molecules (including water) are diamagnetic. The CTU Mega 20 theoretically exploits this property to generate a "pumping" effect on interstitial fluids, which according to its manufacturers may facilitate oedema drainage and transport of substances through the tissues.

Proposed Mechanisms of Action

The mechanisms of action attributed to high-intensity PEMF therapy are largely proposed and theoretical, based on biophysical principles and the known effects of conventional PEMF therapy. The main ones include:

Effects on microcirculation: Evidence suggests that pulsed electromagnetic fields contribute to improving local microcirculation. Proposed mechanisms include nitric oxide-mediated vasodilation and a possible improvement in capillary blood flow. Some studies have already observed these effects (Pilla, 2013).

Modulation of cellular membrane permeability: High-intensity electromagnetic fields may transiently modify the permeability of cell membranes. According to available data, this effect could facilitate the exchange of substances between the intracellular and extracellular environments.

Diamagnetophoresis: This is perhaps the most specific concept of the CTU Mega 20. Diamagnetophoresis refers to the transport of diamagnetic substances (such as anti-inflammatory drugs or hyaluronic acid) through tissues using the electromagnetic field as a driving force. This mechanism allows therapeutic substances to penetrate to greater depth than other transcutaneous transport techniques.

Anti-inflammatory and analgesic effect: PEMF therapy in general has shown, according to various systematic reviews, potential to modulate the inflammatory response and contribute to pain reduction. Proposed mechanisms include modulation of pro-inflammatory cytokines and stimulation of endorphin production. These effects have been observed more consistently with PEMF therapy.

Oedema reduction: The diamagnetic "pumping" effect of the device may facilitate drainage of fluid accumulated in the tissues, contributing to the reduction of post-traumatic or post-surgical oedema.

Proposed Indications

According to the available literature and published clinical experience, the main indications for which high-intensity PEMF therapy has been explored include:

• Post-traumatic and post-surgical oedema: may contribute to oedema reduction as a complement to other conventional measures (cryotherapy, compression, elevation).
• Chronic musculoskeletal pain: tendinopathies (epicondylitis, rotator cuff tendinopathy, patellar tendinopathy), knee, hip and hand osteoarthritis, and non-specific chronic low back pain.
• Peripheral neuropathies: as a complement in the management of peripheral neuropathic pain, although the specific evidence is still preliminary.
• Chronic inflammatory processes: evidence suggests a possible inflammation-modulating effect that could complement pharmacological treatment.
• Facilitation of bone consolidation: PEMF therapy in general has its most established indication in this area (FDA-approved for delayed-union fractures).

It is essential to stress that none of these indications should be interpreted as an alternative to established medical treatments. High-intensity PEMF therapy is always proposed as a complementary tool within a multidisciplinary therapeutic approach.

Scientific Evidence: What We Know and What We Don't

Evidence on PEMF in General

Pulsed electromagnetic field therapy has an extensive body of scientific evidence, especially for certain indications:

• Knee osteoarthritis: The Cochrane systematic review by Li et al. (2013) evaluated the efficacy of PEMF in knee osteoarthritis and identified evidence suggesting a statistically significant reduction in pain and functional improvement compared with placebo. The authors concluded that PEMF therapy may contribute to clinical improvement.
• Musculoskeletal pain: Vavken et al. (2009) conducted a systematic review and meta-analysis on the efficacy of PEMF in the treatment of musculoskeletal pain. Their results indicated a significant analgesic effect, especially in lateral epicondylitis and low back pain, although with heterogeneity among included studies.
• Fracture consolidation: Long-standing evidence exists on the use of PEMF to facilitate consolidation of delayed-union or non-union fractures. The review by Griffin et al. (2011) for the Cochrane Collaboration found suggestive evidence of benefit in fractures.
• Fibromyalgia: Some reviews, such as Giusti et al. (2017), have evaluated PEMF in fibromyalgia with preliminary results suggesting a reduction in pain.

Specific Evidence on the CTU Mega 20

The specific scientific evidence on the CTU Mega 20 device is less extensive by definition than that for conventional PEMF therapy. Most of the published literature comes from Italian research groups. Bacci et al. (2015) published a study on the use of high-intensity diamagnetic field therapy in the treatment of oedema and post-surgical pain in hand surgery, reporting favourable results in terms of oedema reduction and pain relief.

Transparency about the evidence: At GNeuro we consider it essential to be honest with our patients. High-intensity PEMF therapy is a technology that, according to emerging evidence, may contribute as a therapeutic complement. More randomised controlled trials are still needed to definitively establish its efficacy and determine which patients benefit most.

What a Treatment Session Is Like

High-intensity PEMF treatment is a non-invasive and painless procedure. A typical session at GNeuro unfolds as follows:

• Duration: each session lasts between 20 and 30 minutes, depending on the area to be treated and the clinical indication.
• Preparation: the patient sits comfortably and the area to be treated is exposed. In cases where diamagnetophoresis is used, a gel or therapeutic substance is applied to the skin beforehand.
• Application: the device head is placed over the target area. The patient usually feels a mild warmth, slight vibration or, in some cases, no particular sensation at all.
• Frequency: standard protocols include between 6 and 10 sessions, at a frequency of 2 to 3 sessions per week, although the plan is adapted to each patient's individual needs.
• Post-treatment: no rest time is required after the session. The patient can resume normal activities immediately.

Safety and Contraindications

Pulsed electromagnetic field therapy is generally considered a modality with a favourable safety profile. Side effects reported in the literature are minimal and, when they occur, are usually transient:

• Localised heat sensation (usually mild and self-limiting).
• Slight transient skin redness at the site of application.
• Rarely, mild discomfort or tingling sensation.

Nevertheless, there are absolute contraindications that must be strictly observed:

• Pacemakers or other implanted electronic devices: the electromagnetic field may interfere with their function.
• Metallic implants in the treatment area: may concentrate electromagnetic energy and generate local heating.
• Pregnancy: as a precautionary principle, given that there are insufficient safety studies.
• Active neoplasms: electromagnetic stimulation could theoretically influence cell proliferation.
• Uncontrolled epilepsy: especially if the application area is close to the skull.

At GNeuro, before starting any high-intensity PEMF treatment, a full medical assessment is carried out to rule out contraindications and determine the suitability of treatment for each patient.

High-Intensity PEMF at GNeuro: Integration in Neurorehabilitation

GNeuro is one of the few centres in Galicia equipped with the CTU Mega 20 high-intensity pulsed electromagnetic field system, integrated within a comprehensive robotic neurorehabilitation programme.

Our centre's approach is based on combining multiple technologies within personalised rehabilitation programmes. High-intensity PEMF therapy is not used as an isolated treatment, but as a complement that may help improve tissue conditions before or after other interventions:

• Pre-robotic therapy: may contribute to reducing oedema and pain, preparing the area for rehabilitation sessions with devices such as the exoskeleton-assisted gait trainer or the upper limb rehabilitation robot.
• Post-rehabilitation session: as an analgesic and anti-inflammatory complement after intensive robotic therapy sessions.
• Neuropathic pain management: as part of a multimodal approach to pain in neurological patients, always as a complement to prescribed pharmacological treatment.
• Comprehensive programme: combination with other robotic neurorehabilitation technologies and conventional therapy for a complete approach.

This integration ensures that high-intensity PEMF treatment is framed within a global therapeutic strategy, supervised by a multidisciplinary team including a rehabilitation physician, a physiotherapist specialised in neurorehabilitation, and a speech-language therapist.

Frequently Asked Questions

References